rucaparib explored for high-risk ovarian cancer
Published 3 years ago • 85 plays • Length 4:20Download video MP4
Download video MP3
Similar videos
-
3:06
rucaparib maintenance therapy for high-risk ovarian cancer
-
5:11
defining rucaparib’s value in recurrent ovarian cancer
-
2:07
rucaparib in platinum-sensitive ovarian cancer
-
4:25
rucaparib: clinical activity in relapsed ovarian cancer
-
3:11
rucaparib in recurrent ovarian cancer: ariel3 trial
-
5:17
outlook for patients with high-risk ovarian cancer
-
2:58
rucaparib for relapsed ovarian cancer: safety profile
-
2:05
future directions in high-risk ovarian cancer
-
2:15
toxicities associated with rucaparib for the treatment of ovarian cancer
-
5:18
rucaparib for ovarian cancer
-
3:39
case overview: high-risk ovarian cancer
-
1:21
rucaparib may improve pfs in patients with ovarian cancer
-
2:58
high-risk advanced ovarian cancer: chemotherapy options
-
1:41
the clinical activity of rucaparib in patients with ovarian cancer
-
6:54
current landscape of parp inhibition in ovarian cancer
-
4:31
maintenance therapy for advanced ovarian cancer
-
3:42
gynecologic oncology at asco 2022: athena–mono trial (rucaparib monotherapy) for ovarian cancer
-
1:42
phase iii results for rucaparib in ovarian cancer
-
3:15
patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis